CVMP adopts a positive opinion for SCOVELLA®, the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome
Reported by Markets Insider · November 9 at 9:00 PM · Summary by Hoofdeck
Boehringer Ingelheim announced that the European Medicines Agency's CVMP has adopted a positive opinion recommending marketing authorization in the EU for SCOVELLA (velagliflozin oral solution), a treatment for hyperinsulinaemia in horses with Equine Metabolic Syndrome. The drug was already approved and introduced in Great Britain earlier this year, and European Commission approval is still pending.
Background
Insulin dysregulation is a metabolic condition in which horses have persistently high insulin levels, and it is strongly linked to laminitis, a painful inflammation of the hoof. Treatment usually focuses on diet, weight control and exercise, and drugs are generally used only when those measures are not enough. A CVMP positive opinion is a recommendation to the European Commission, which makes the final decision on authorization.
Why it matters
Insulin dysregulation affects a large share of horses, and laminitis is a serious risk for any horse carrying it.
What you can do
If your horse has been diagnosed with insulin dysregulation or Equine Metabolic Syndrome, talk with your veterinarian about whether this or other management options fit your horse.
Written by Hoofdeck from the report by Markets Insider. Background is general information, not advice about your horse; if you are worried, call your vet.